Stephen Moore, Ph.D., FACMG, MBA

Director Cytogenetics

Director Molecular Diagnostics

Program Director ABMGG Medical Genetics Training Program

Associate Professor, Molecular and Medical Genetics

Biographical Sketch

Dr. Moore is ABMG board certified in both Clinical Cytogenetics and Clinical Molecular Genetics, completing fellowships at Cedars-Sinai/UCLA and OHSU respectively, and is a fellow of the American College of Medical Genetics.  Dr. Moore received his M.S. in Biology from California State University, and his Ph.D. in Environmental Toxicology from the University of California.  He was a Career Development Fellow with the Medical Research Council (MRC) Radiation and Genome Stability Unit in Harwell, UK, the Gray Laboratory, and the MRC Molecular Hematology Laboratory (U. Oxford), where he developed chromosomal assays and targeted radiation techniques for studying long-term effects of radiation exposure, also a focus of his Ph.D. research.  Dr. Moore had a short fellowship at City of Hope developing tools for chromosomal microarray analysis of single cells. Presently, his laboratory interests include chromosomal microarray analysis for postnatal, prenatal and oncology applications and the development of next-generation sequencing panels rare genetic disorders; the overarching goal being to provide genomic tools to guide personalized medicine into the future.  Dr. Moore joined the faculty of Oregon Health & Science University in 2009.



  1. Winters C, Chen A, Moore S, Traer E, Dunlap J.  Acute promyelocytic leukemia presenting with features of metastatic osseous disease. Leukemia Res Rep 2018, 9: 36-37.
  2. Raess PW, Moore SR, Cascio MJ, Dunlap J, Fan G, Gatter K, Olson SB, Braziel RM. MYC immunohistochemical and cytogenetic analysis are required for identification of clinically relevant aggressive B cell lymphoma subtypes.  Leuk Lymphoma 2017 Sep 3:1-8.
  3.   Lawce H, Szabo E, Torimaru Y, Davis C, Osterberg K, Olson S and Moore S. MECOM (EVI1) Rearrangements: A Review and Case Report of Two MDS Patients with Complex 3q Inversion/Deletions. JAGT 2017, 43(1):9-14. 
  4.  Long T, Lawce H, Durum C, Moore S, Olson S, Gatter K, Troxell ML. The New Equivocal:  Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines.  Am J Clin Path. 2015 144(2): 253-262.
  5. Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, Tomlins SA, Reinig E, Beadling C, Andersen M, Corless CL. Assessing Copy Number Alterations in Targeted, Amplicon-Based Next-Generation Sequencing Data.  J Mol Diagnostics 2015 Jan;17(1):53-63.
  6. Singh K, Moore S, Sandoval M, Balzer B, Frishberg D, Lewin S, Schreck R, Raffel L. Congenital malignant melanoma: a case report with cytogenetic studies.  Am J Dermatopath. 2013 Dec;35(8).
  7. Kratochvil, Stewart and Moore.  Mammary analogue secretory carcinoma of salivary glands:  a report of two cases in the lips and a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Nov;114(5):630-5.
  8. Chakrapani AL, White CR, Korcheva V, White K, Lofgren S, Zonana J, Moore S, Krol A, Mansoor A. Congenital Extrarenal Malignant Rhabdoid Tumor in an Infant with Distal 22q11.2 Deletion Syndrome: the Importance of SMARCB1.  Am J Dermatopathol. 2012 Aug;34(6):e77-80. 
Full Bibliography can be found at: Pub Med Bibliography

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More